Radezolid

Radezolid is a novel antibiotic that belongs to the oxazolidinone class. It is currently under development for the treatment of bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

History

Radezolid was first synthesized by Rib-X Pharmaceuticals, a company that specializes in the development of new antibiotics. The drug is currently in Phase II clinical trials for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP).

Mechanism of Action

Radezolid works by inhibiting protein synthesis in bacteria, thereby preventing them from growing and multiplying. It does this by binding to the bacterial ribosome, a complex molecular machine that synthesizes proteins.

Clinical Trials

Radezolid has undergone Phase I and II clinical trials. In Phase I trials, the drug was found to be safe and well-tolerated in healthy volunteers. In Phase II trials, radezolid was found to be effective in treating patients with cSSSI and CABP.

Side Effects

As with all drugs, radezolid may cause side effects. These can include nausea, vomiting, diarrhea, and headache. More serious side effects can include anemia, thrombocytopenia, and neuropathy.

Future Development

Radezolid is currently in Phase II clinical trials. If these trials are successful, the drug will move on to Phase III trials, where it will be tested in a larger number of patients. If it passes Phase III trials, radezolid could be approved for use by the Food and Drug Administration (FDA).

See Also

• Oxazolidinone
• Antibiotic resistance
• Methicillin-resistant Staphylococcus aureus
• Vancomycin-resistant enterococci

• 
  Radezolid